drugset / Trial / NCT03853694

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694

Phase 4 Completed 167 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare total opioid consumption by subjects in different treatment groups. Another purpose of this study is to assess how well EXPAREL works, collect any safety data and assess your satisfaction using EXPAREL.

Timeline

Start
2019-03-04
Primary completion
2020-01-09
Completion
2020-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other
Subject Morphine Other / unclassified 50 ug Intrathecal
Subject Morphine Other / unclassified 150 ug Intrathecal

Indications

No indication recorded.